An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC

Status: Closed to Accrual

Learn more:

• https://clinicaltrials.gov/study/NCT03909334
• See news release

Abstracts/Posters/Presentations:

• X Le, J Patel, E Shum, J Sabari, C Baik, R Sanborn, K Shu, C Kim, M Jo Fidler, R Hall, N Hanna, J Gray, JV Heymach, A Saltos. LBA71 – A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis)(HCRN-LUN18-335). Presented as a mini oral session at the 2023 EMSO Congress. See abstract. 
• A. Saltos, C. Baik, R.E. Sanborn, E. Shum, C. Kim, R. Hall, M.J. Fidler, C.A. Shu, G. Otterson, J. Patel, K.K. Wong, N. Hanna, J. Gray, J. Heymach, X. Le. RAMOSE: An Open-Label Randomized Phase II Study of Osimertinib with or without Ramucirumab in TKI-naïve EGFR-mutant Metastatic NSCLC. Presented at the IASLC 2020 World Conference on Lung Cancer. See abstract.

Study Contact: studies@hoosiercancer.org; (317) 921-2050.